Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its ...

The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

DexCom reported worldwide revenue of $1.26 billion versus $1.11 billion a year earlier, marking 13% reported growth and 12% organic. U.S. Q4 revenue climbed 11% year over year to $892 million, while ...

DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q4 2025 Earnings Call Transcript February 20, 2026 Operator: Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care Fourth Quarter 2025 ...

In addition to Jefferies, Dexcom also received a Buy from Canaccord Genuity’s William Plovanic in a report issued today. However, on the same day, Barclays maintained a Sell rating on Dexcom (NASDAQ: ...

Here's something we want to shout from the grocery-store rooftops: Eating healthy doesn't have to break the bank. While we can't control rising food prices, real people everywhere are still losing ...

Autonomous Vehicles, ML, Quantum computing, smart homes, Telemedicine, Wearable devices The Intersection of Technology and ...

Integra LifeSciences cuts 65 jobs at Princeton facility following device recall, joining wave of medtech layoffs affecting ...

Feb 18 (Reuters) - Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.